Published in Am J Kidney Dis on November 01, 1991
FVB mouse genotype confers susceptibility to OVE26 diabetic albuminuria. Am J Physiol Renal Physiol (2010) 0.99
An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2007) 0.92
Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6. Lab Invest (2013) 0.86
Emerging therapies for diabetic nephropathy patients: beyond blockade of the Renin-Angiotensin system. Nephron Extra (2012) 0.78
6. Diabetic Nephropathy. EJIFCC (2009) 0.77
What the radiologist needs to know about the diabetic patient. Insights Imaging (2011) 0.77
Mesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic Nephropathy. Stem Cells Int (2016) 0.75
Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis. Sci Rep (2016) 0.75
Association of vascular endothelial growth factor -634G/C and receptor for advanced glycation end products G82S gene polymorphisms with diabetic retinopathy. Int J Ophthalmol (2016) 0.75
Impaired Albumin Uptake and Processing Promote Albuminuria in OVE26 Diabetic Mice. J Diabetes Res (2016) 0.75
Renal kallikrein activation and renoprotection after dual blockade of renin-angiotensin system in diet-induced diabetic nephropathy. J Diabetes Res (2015) 0.75
Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med (1999) 15.69
Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis (1998) 7.79
Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis (1998) 5.28
The quality of life of patients with end-stage renal disease. N Engl J Med (1985) 5.10
Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol (2001) 4.36
Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet (1999) 4.04
Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med (1989) 3.67
Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int (2006) 3.58
Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA (1993) 3.10
Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis (1999) 3.09
Report of a National Conference on Donation after cardiac death. Am J Transplant (2006) 3.04
Delayed graft function: risk factors and implications for renal allograft survival. Transplantation (1997) 3.01
Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr (2002) 2.96
Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant (2001) 2.94
Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int (2001) 2.92
Median sensory distal amplitude and latency: comparisons between nonexposed managerial/professional employees and industrial workers. Am J Ind Med (1993) 2.87
Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int (2006) 2.85
Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol (2001) 2.80
Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis (2000) 2.65
Effect of waiting time on renal transplant outcome. Kidney Int (2000) 2.57
The impact of comorbid and sociodemographic factors on access to renal transplantation. JAMA (1993) 2.54
Long-term survival in renal transplant recipients with graft function. Kidney Int (2000) 2.38
Determinants of discard of expanded criteria donor kidneys: impact of biopsy and machine perfusion. Am J Transplant (2008) 2.38
Occupational and other exposures associated with male end-stage renal disease: a case/control study. Am J Public Health (1990) 2.26
Noncompliance in hemodialysis: predictors and survival analysis. Am J Kidney Dis (1998) 2.16
Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol (2000) 2.16
Predictors of type of vascular access in hemodialysis patients. JAMA (1996) 2.00
CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity. J Pharmacol Exp Ther (1989) 1.99
Survival advantage in Asian American end-stage renal disease patients. Kidney Int (1999) 1.98
Mortality after kidney transplantation: a comparison between the United States and Canada. Am J Transplant (2006) 1.92
Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation (2000) 1.90
Biocidal activities of glutaraldehyde and related compounds. J Appl Bacteriol (1967) 1.89
Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney. J Biol Chem (1997) 1.84
Racial and gender variation in use of diagnostic colonic procedures in the Michigan Medicare population. Med Care (1999) 1.82
Transforming growth factor-beta. Murine glomerular receptors and responses of isolated glomerular cells. J Clin Invest (1989) 1.82
The dose of hemodialysis and patient mortality. Kidney Int (1996) 1.82
Effects of age, sex, and anthropometric factors on nerve conduction measures. Muscle Nerve (1992) 1.80
Competition and efficiency in the end stage renal disease program. J Health Econ (1983) 1.79
Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis (1998) 1.78
Practice patterns, case mix, Medicare payment policy, and dialysis facility costs. Health Serv Res (1999) 1.78
Geographic variability in access to primary kidney transplantation in the United States, 1996-2005. Am J Transplant (2007) 1.77
Socioeconomic status and end-stage renal disease in the United States. Kidney Int (1994) 1.75
The impact of vascular access for haemodialysis on patient morbidity and mortality. Nephrol Dial Transplant (1997) 1.73
ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int (1996) 1.71
Comparison of patient and technique survival in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis: a multicenter study. Perit Dial Int (1990) 1.70
Recovery and utilization of deceased donor kidneys from small pediatric donors. Am J Transplant (2006) 1.68
Differences in access to cadaveric renal transplantation in the United States. Am J Kidney Dis (2000) 1.67
Use of community versus individual socioeconomic data in predicting variation in hospital use. Health Serv Res (1998) 1.64
Geographic differences in event rates by model for end-stage liver disease score. Am J Transplant (2006) 1.62
The effect of bystander CPR on survival of out-of-hospital cardiac arrest victims. Am Heart J (1985) 1.61
Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. Am J Transplant (2001) 1.60
Catastrophic antiphospholipid syndrome: response to repeated plasmapheresis over three years. Arthritis Rheum (1997) 1.58
Geographic variation in end-stage renal disease incidence and access to deceased donor kidney transplantation. Am J Transplant (2010) 1.55
Survival analysis of patients undergoing dialysis. JAMA (1987) 1.53
Implications for health care policy. A social and demographic profile of hemodialysis patients in the United States. JAMA (1981) 1.51
Effect of race on access to recombinant human erythropoietin in long-term hemodialysis patients. JAMA (1994) 1.51
Body size, dose of hemodialysis, and mortality. Am J Kidney Dis (2000) 1.48
Popliteal artery injury complicating arthroscopic menisectomy. Am J Surg (1988) 1.47
The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation (2001) 1.46
Patterns of low incidence of treated end-stage renal disease among the elderly. Am J Kidney Dis (1992) 1.45
Outcome of end-stage renal disease in patients with rare causes of renal failure. I. Inherited and metabolic disorders. Q J Med (1989) 1.43
Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis (2000) 1.43
Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials (1996) 1.42
Hemodialysis vascular access morbidity in the United States. Kidney Int (1993) 1.41
Liver cysts in patients with autosomal dominant polycystic kidney disease. Am J Med (1980) 1.41
Causes of death in dialysis patients: racial and gender differences. J Am Soc Nephrol (1994) 1.40
Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol (2001) 1.40
Using USRDS generated mortality tables to compare local ESRD mortality rates to national rates. Kidney Int (1992) 1.38